Clinical Trials Education Center
About Clinical Trials
Clinical trials for pulmonary fibrosis treatment are research studies that explore whether a medical strategy, treatment, or device is safe and effective for humans. These studies also may show which medical approaches work best for certain illnesses or groups of people. Clinical trials for pulmonary fibrosis treatment produce the best data available for health care decision making.
The purpose of clinical trials is research, so the studies follow strict scientific standards. These standards protect patients and help produce reliable study results.
Find a Clinical Trial
The PFF Clinical Trial Finder is a comprehensive list of clinical trials for pulmonary fibrosis related conditions.
Systemic Sclerosis With and Without Interstitial Lung Disease
Study ID: NCT04948554
Trial Phase: Phase 1b
Intervention: Subcutaneous (SC) Injection
Sponsor: Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
Contact: Trialsites@merck.com; 1.888.577.8839
PFF Community Registry
Study ID: NCT05382572
Sponsor: Pulmonary Fibrosis Foundation, University of Michigan
Contact: email@example.com & firstname.lastname@example.org
Interstitial Lung Disease & Obstructive Sleep Apnea
Study ID: NCT03901534
Intervention: Device - Auto-CPAP
Sponsor: Columbia University
Contact: email@example.com; 212.342.0256
Idiopathic Pulmonary Fibrosis
Study ID: NCT05671835
Trial Phase: Phase 2
Intervention: Oral tablet
Sponsor: Tvardi Therapeutics
Drug Development Pipeline for PF & IPF
In the PF Drug Development Pipeline you can learn about the latest in drug development for PF-related conditions. Use the filters on the left-hand side to narrow results by study phase, intervention type, condition, and more.
Phases of Clinical Trials
Clinical trials investigate dosage, safety, efficacy and potential outcomes of drugs or treatments in disease-specific populations through controlled trials. There are typically three stages or phases of clinical trials that must be performed before a drug or treatment may be submitted to regulatory agencies (ie: U.S. Food & Drug Administration) for approval. Prior to commencing a clinical trial, a drug must have demonstrated safety and efficacy in a laboratory model.
Researchers test a new drug or treatment in a small group of people (usually 20-100 volunteers) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects. Doses start small and increase in different patient groups until the desired effect of the treatment is observed or side effects of the treatment become too severe.
The drug or treatment is given to a larger group of people (up to several hundred volunteers) to see if it is effective and to further evaluate its safety. Most Phase 2 studies have randomized control (placebo) groups and treatment groups. Most of these trials are “double-blind” which means that neither the patients nor the researchers know whether the patient is receiving the treatment or placebo.
The drug or treatment is given to large groups of people (several hundred to thousands of volunteers) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments (or placebo), and collect information that will allow the drug or treatment to be used safely. Phase 3 trials are also randomized and most are double-blind.
The drug or treatment has been FDA approved for marketing. These studies can include post-market requirement and commitment studies that are required of or agreed to by the study sponsor. Phase 4 trials gather additional information about a drug's safety, efficacy, or optimal use.